Compugen Ltd
NASDAQ:CGEN
Gross Margin
Compugen Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IL |
|
Compugen Ltd
NASDAQ:CGEN
|
131.6m USD |
70%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
56%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
152.1B USD |
41%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
135.9B USD |
60%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
53%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.8B CHF |
37%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
31.9B USD |
54%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
183.4B CNY |
42%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
24.4B USD |
35%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
24B USD |
60%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
18.9B EUR |
44%
|
Compugen Ltd
Glance View
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Compugen Ltd's most recent financial statements, the company has Gross Margin of 70.2%.
You don't have any saved screeners yet